Technical Analysis for OXB - Oxford Biomedica Plc

Grade Last Price % Change Price Change
D 1018.0 0.79% 8.00
OXB closed up 0.79 percent on Wednesday, May 12, 2021, on 86 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Down
Historical OXB trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Bullish Engulfing Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish 0.79%
Down 3 Days in a Row Weakness 0.79%
Lower Bollinger Band Touch Weakness 0.79%
Older End-of-Day Signals for OXB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Oxford Biomedica Plc Description

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pipe Disease Cancer Diseases Xf Therapy Platform Technology Cancers Cell Therapy Cell Therapy Product Gene Delivery Molecular Genetics Parkinson's Disease

Is OXB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1126.53
52 Week Low 700.3737
Average Volume 139,037
200-Day Moving Average 918.67
50-Day Moving Average 1019.88
20-Day Moving Average 1056.80
10-Day Moving Average 1044.00
Average True Range 37.38
ADX 11.27
+DI 19.13
-DI 21.95
Chandelier Exit (Long, 3 ATRs ) 1014.39
Chandelier Exit (Short, 3 ATRs ) 1097.14
Upper Bollinger Band 1112.52
Lower Bollinger Band 1001.08
Percent B (%b) 0.15
BandWidth 10.54
MACD Line 1.66
MACD Signal Line 11.03
MACD Histogram -9.3742
Fundamentals Value
Market Cap 837.07 Million
Num Shares 82.2 Million
EPS -11.60
Price-to-Earnings (P/E) Ratio -87.76
Price-to-Sales 10.08
Price-to-Book 6.53
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1052.50
Resistance 3 (R3) 1049.33 1034.67 1046.75
Resistance 2 (R2) 1034.67 1025.88 1036.25 1044.83
Resistance 1 (R1) 1026.33 1020.45 1030.50 1029.50 1042.92
Pivot Point 1011.67 1011.67 1013.75 1013.25 1011.67
Support 1 (S1) 1003.33 1002.88 1007.50 1006.50 993.08
Support 2 (S2) 988.67 997.45 990.25 991.17
Support 3 (S3) 980.33 988.67 989.25
Support 4 (S4) 983.50